logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
N

Nadia Harbeck

lmu university hospital

131H-index
2.1KPaper Count
8.5WCitation Count
Published Papers 558
Publication Date
logo
A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2− Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence
errCancers
IF4.4
err2026-07-23
err0
errOAAI
errTimothy Pluard; Thomas Grinda; Rodrigo Dienstmann; Marc Thill; Beata Korytowsky; Connie Chen; Sofiya Portuhay; Elizabeth M. Salvo-Halloran; Imtiaz A. Samjoo; Nadia Harbeck
errShare
errSave
Reply to the letter to the editor ‘The curious incident of the T-DXd alone arm killed at (DESTINY-Breast) eleven o'clock’ by Orlandi
errAnnals of Oncology
IF65.4
err2026-04-22
err0
PREAI
errN. Harbeck; S. Modi; L. Pusztai; J-F Boileau
errShare
errSave
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al.
errAnnals of Oncology
IF65.4
err2025-12-20
err0
PREAI
errOleg Gluz; Ronald Kates; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck
errShare
errSave
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
errRadiotherapy and Oncology
IF5.3
err2025-12-11
err0
errOAAI
errEvert S.M. van Aken; Ajeet Kumar Gandhi; Sean M. O’Cathail; Gerben Borst; Jorge Barriuso; Emmanouil Fokas; Luis Castelo-Branco; Anne Hansen Ree; Evandro de Azambuja; Stephanie Kroeze; Ilaria Colombo; Antonin Levy; Carmen Criscitiello; Maximilian Niyazi; Nadia Harbeck; Ewa Szutowicz; Gabor Liposits; Marcel Verheij; Isabelle Ray-Coquard; Paolo Tarantino
errShare
errSave
Comparison of Prosigna® Assay and Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Results in Early-Stage Breast Cancer Patients
errBreast Care
IF2.1
err2025-12-01
err0
PREAI
errRickerl, Laura; Bartsch, Harald; Harbeck, Nadia; Hofmann, Daniel Maria; Kolben, Thomas; Degenhardt, Tom; Sotlar, Karl; Wuerstlein, Rachel
errShare
errSave
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry
errESMO Open
IF8.3
err2025-11-27
err0
errOAAI
errU. Nitz; M. Graeser; O. Gluz; S. Kümmel; M. Just; C. Jackisch; C. zu Eulenburg; M. Christgen; N. Harbeck
errShare
errSave
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
errESMO Open
IF8.3
err2025-11-21
err0
errOAAI
errG. Zhang; H. Ni; L. Mishieva; S. Bartels; M. Christgen; H. Christgen; L.D. Kandt; M. Raap; R.E. Kates; O. Gluz; M. Graeser; S. Kümmel; U. Nitz; C. Plass; U. Mansmann; C. zu Eulenburg; C. Gerhäuser; H.H. Kreipe; N. Harbeck
errShare
errSave
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021
errnpj Breast Cancer
IF7.6
err2025-11-13
err0
errOAAI
errAlexandra Thomas; Anthony Rhoads; Erica L. Mayer; Seamus O’Reilly; Nadia Harbeck; Giuseppe Curigliano; Yang Zhou; Virginie Adam; Nancy Chan; Kristin M. Conway; Michail Ignatiadis; Kevin Kalinsky; Angela DeMichele; Paul A. Romitti
errShare
errSave
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
errAnnals of Oncology
IF65.4
err2025-10-21
err0
errOAAI
errNadia Harbeck; Shanu Modi; Lajos Pusztai; Shinji Ohno; Jiong Wu; Sung-Bae Kim; Atsushi Yoshida; Alessandra Fabi; Xuchen Cao; Rona Joseph; Rubi Li; Bogdan Żurawski; Santiago Escrivá-de-Romaní; Renata Meneguetti; Archara Supavavej; Shin-Cheh Chen; Zhenzhen Liu; Catherine Kelly; Giuseppe Curigliano; William F. Symmans; Mohammad Gufran; Jun Ke; Adam Konpa; Pia Herbolsheimer; Jean-François Boileau
errShare
errSave
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
errAnnals of Oncology
IF65.4
err2025-10-18
err0
errOAAI
errE.Y.T. Wong; L. Verlingue; M. Aldea; M.A. Franzoi; R. Umeton; S. Halabi; N. Harbeck; A. Indini; A. Prelaj; E. Romano; E. Smyth; I.B. Tan; A. Valachis; J. Vibert; I.C. Wiest; Y.H. Yang; S. Gilbert; G. Kapetanakis; G. Pentheroudakis; M. Koopman; J.N. Kather
errShare
errSave
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours
errJournal of Cellular and Molecular Medicine
IF4.2
err2025-10-09
err0
errOAAI
errAntonio Sechi; Jolein Mijnes; Sophia Villwock; Michael Rose; Florian Steib; Sarah Bringezu; Jonas Berger; Carmen Schalla; Sonja von Serenyi; Jana Dietrich; Nadina Ortiz-Brüchle; Lara Heij; Jan Bednarsch; Oleg Gluz; Ulrike Nitz; Nadia Harbeck; Monika Graeser; Christine zu Eulenburg; Mohammad Parsa Mohammadian; Katarzyna Jóźwiak; Hans-Heinrich Kreipe; Matthias Christgen; Martin Radner; Danny Jonigk; Edgar Dahl
errShare
errSave
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
errNature Medicine
IF50
err2025-10-08
err0
errOAAI
errShanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
errShare
errSave
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
errnpj Breast Cancer
IF7.6
err2025-10-02
err0
errOAAI
errJavier Cortes; Oleg Lipatov; Seock-Ah Im; Anthony Goncalves; Keun Seok Lee; Peter Schmid; Kenji Tamura; Laura Testa; Shoichiro Ohtani; Nadia Harbeck; Sherene Loi; Roberto Salgado; Vassiliki Karantza; Jaime Mejia; Razvan Cristescu; Andrey Loboda; Michael Nebozhyn; Petar Jelinic; Lingkang Huang; Eric P. Winer
errShare
errSave
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders
errJOURNAL OF CLINICAL INVESTIGATION
IF13.6
err2025-10-01
err2
errOAAI
errZhang, Guokun; Jurinovic, Vindi; Bartels, Stephan; Christgen, Matthias; Christgen, Henriette; Kandt, Leonie Donata; Mishieva, Lidiya; Ni, Hua; Raap, Mieke; Klein, Janin; Katzke, Anna-Lena; Hofmann, Winfried; Steinemann, Doris; Kates, Ronald E.; Gluz, Oleg; Graeser, Monika; Kummel, Sherko; Nitz, Ulrike; Plass, Christoph; Lehmann, Ulrich; Eulenburg, Christine zu; Mansmann, Ulrich; Gerhauser, Clarissa; Harbeck, Nadia; Kreipe, Hans H.
errShare
errSave
Macroareolar Changes following Periareolar Mastopexy: A Postoperative Assessment
errBreast Care
IF2.1
err2025-10-01
err0
PREAI
errPeter, Therese; Koban, Konstatin C.; Ehrl, Denis; Harbeck, Nadia; Kahlert, Steffen; Luczak, Carolin; Schmid, Johannes; Wuerstlein, Rachel; Hagemann, Friederike
errShare
errSave
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2025-09-01
err3
errOAAI
errLambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.
errShare
errSave
Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review
errFrontiers in Oncology
IF3.3
err2025-08-15
err0
errOAAI
errNadia Harbeck; Adam Brufsky; Chloe Grace Rose; Beata Korytowsky; Connie Chen; Krista Tantakoun; Endri Jazexhi; Do Hoang Vien Nguyen; Meaghan Bartlett; Imtiaz A. Samjoo; Timothy Pluard
errShare
errSave
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
errESMO Open
IF8.3
err2025-08-14
err0
errOAAI
errM. Hamann; M. Christgen; O. Gluz; U. Nitz; S. Kuemmel; M. Braun; M. Thill; R. Wuerstlein; P. Wimberger; A. Hartkopf; C. Schem; M. Zaiss; V. Bjelic-Radisic; M. Just; K. Veselinovic; M. Vincent; M. Graeser; K. Krauss; O. Hoffmann; K. Lüdtke-Heckenkamp; R.E. Kates; C. zu Eulenburg; K. Jóźwiak; S. Burmeister; M. Hauptmann; F. Baehner; P. Schmid; H.-H. Kreipe; N. Harbeck
errShare
errSave
Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline†
errAnnals of Oncology
IF65.4
err2025-08-12
err0
PREAI
errD. Trapani; D. Martins-Branco; G. Curigliano; A. Gennari; G. Pentheroudakis; N. Harbeck
errShare
errSave
CDK4/6-Inhibitor in Kombination mit Aromatasehemmer wirksam bei metastasiertem Hidradenokarzinom
errjournal der deutschen dermatologischen gesellschaft
IF0
err2025-08-11
err0
errOAAI
errValerie Glatzel; Dirk Tomsitz; Michaela Maurer; Simone Schneider; Stefan Brunner; Nadia Harbeck; Lucie Heinzerling
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
C
Charles M. Perou
H-index: 193 · Papers: 2.0K
D
D. Gareth Evans
H-index: 182 · Papers: 2.5K
E
Eric P. Winer
H-index: 170 · Papers: 1.6K
G
Giuseppe Viale
H-index: 157 · Papers: 1.3K
M
Martine Piccart
H-index: 149 · Papers: 1.6K
View more